LEADER 03484nam 22005533a 450 001 9910346662003321 005 20250203235435.0 010 $a9783038974888 010 $a3038974889 024 8 $a10.3390/books978-3-03897-488-8 035 $a(CKB)4920000000095047 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/59150 035 $a(ScCtBLL)3ad65de0-d246-4685-9491-9066c23e29c9 035 $a(OCoLC)1163853099 035 $a(oapen)doab59150 035 $a(EXLCZ)994920000000095047 100 $a20250203i20192019 uu 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aSelected Papers from CUBANNI 2017-"The Fourth International Workshop of Neuroimmunology"$fDario Siniscalco, Maria De los Angeles Robinson Agramonte, Carlos Alberto Gonçalves 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2019 210 1$aBasel, Switzerland :$cMDPI,$d2019. 215 $a1 electronic resource (170 p.) 311 08$a9783038974871 311 08$a3038974870 330 $aIn parallel with a decrease/stabilization in the use of internationally controlled drugs, the market of novel psychoactive substances (NPS) continues increasing, year after year, with the Internet playing a pivotal role in contributing to this complex scenario. At times, although misleading, the terms 'legal highs' or 'research chemicals' have been used to describe these molecules. Overall, about 5% of 19-24-year-old European people have already experimented with them, because both NPS' intense psychoactive effects and their virtual non-detectability in routine drug screenings. Although 'novel' typically refers to molecules that have recently become a reason of current/potential public health concern, at times, the NPS scenario may indeed focus on pharmaceutical molecules. These may have either not entered the market, or are currently prescribed, with their potential for misuse resulting from the relating high dosages/idiosyncratic ways of self-administration. A concurrent use of a range of different NPS, and/or medications, is frequently being reported and this may be a reason of further clinical complications. Given their complex pharmacodynamics, there are increasing levels of concern about the onset of acute/chronic psychopathological associated with NPS intake. This Special Issue aims at providing an overview of a range of NPS-related issues, e.g., preclinical, epidemiological, and clinical pharmacological; the medical and psychopathological consequences associated with their intake; and, finally, the analytical chemistry and forensic analysis challenges associated with the NPS phenomenon. 606 $aNeurology and clinical neurophysiology$2bicssc 610 $aErythropoyetine 610 $aEEG 610 $aEpilepsy 610 $aParkinson disease 610 $aneurodevelopmenal disorders 610 $aTMS 610 $aautism 610 $aoxidative stress 610 $aneuroplasticity 615 7$aNeurology and clinical neurophysiology 700 $aSiniscalco$b Dario$01788048 702 $aDe los Angeles Robinson Agramonte$b Maria 702 $aGonçalves$b Carlos Alberto 801 0$bScCtBLL 801 1$bScCtBLL 906 $aBOOK 912 $a9910346662003321 996 $aSelected Papers from CUBANNI 2017-"The Fourth International Workshop of Neuroimmunology"$94322368 997 $aUNINA